Biodexa enrolls 100th patient in Serenta Phase 3 eRapa trial in familial adenomatous polyposis

• Biodexa reached 100 enrolled patients in the Serenta registrational Phase 3 trial of eRapa in familial adenomatous polyposis.
• No trial results were presented; the next readout is a pre-specified futility analysis expected early next year.
• Management expects the study’s key interim decision point sooner than planned, based on the pace of disease progression events.
• Database lock is now targeted around the end of next year, potentially accelerating the program’s timeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130830PRIMZONEFULLFEED1001277725) on October 13, 2026, and is solely responsible for the information contained therein.